Related Experiment Video
Updated: Aug 21, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
[MAOB: a modifier gene in phenylketonuria?]
Aline Ghozlan1, Arnold Munnich
1Inserm U.393, Handicaps génétiques de l'enfant, Tour Lavoisier, Hôpital Necker-Enfants Malades, 149, rue de Sèvres, 75743 Paris 15, France. acghozlan@yahoo.fr
Insights
Phenylketonuria (PKU) can cause cognitive issues due to phenylalanine buildup. Monoamine oxidase B (MAOB) may modify PKU severity by affecting toxic metabolite levels, potentially explaining varied patient outcomes.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Context:
- Phenylketonuria (PKU) is a common inherited metabolic disorder.
- Despite dietary management, PKU patients often face cognitive and behavioral challenges.
- Variability in PKU phenotypes suggests genetic modifiers are at play.
Purpose:
- To investigate the potential role of monoamine oxidase type B (MAOB) as a genetic modifier in PKU.
- To explore how MAOB activity influences phenylethylamine levels and clinical outcomes in PKU patients.
Summary:
- PKU results from phenylalanine hydroxylase deficiency, leading to toxic phenylalanine buildup.
- MAOB degrades phenylethylamine, a toxic phenylalanine metabolite.
- Variations in MAOB activity could explain differing clinical outcomes in PKU patients with similar phenylalanine levels.
Impact:
- MAOB may act as a crucial modifier gene in PKU.
- Understanding MAOB's role could lead to improved PKU management strategies.
- Early-onset phenylethylamine toxicity, potentially mediated by low MAOB activity, may cause irreversible newborn brain damage in PKU.
Abstract:
Phenylketonuria (PKU), the most frequent inborn error of metabolism (1/15,000 live births), is an autosomal recessive condition caused by phenylalanine hydroxylase deficiency. Despite early and strict dietary control, some PKU children still exhibit behavioral and cognitive difficulties suggestive of a partly prenatal brain injury. The reported variability between the cognitive and clinical phenotypes within the same family raises the question of modifying genes in PKU. We suggest here that monoamine oxidase type B, MAOB, an enzyme degrading phenylethylamine, a very toxic metabolite of phenylalanine, could act as a modifying gene since a variant enzymatic activity of MAOB in PKU patients with similar phenylalanine levels would result in different phenylethylamine levels and different clinical outcomes. Finally the report of low MAOB, and consequently expectedly high phenylethylamine levels in neonates is consistent with a phenylethylamine-mediated brain injury possibly causing irreversible damages in PKU newborns prior to onset of the low protein diet.
More Related Videos
Related Concept Videos
Inborn Errors of Metabolism
Pleiotropy
Epistasis Analysis
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Epistasis

